TY - JOUR
AU - Stockert, Lori
AB - IntroductionPsoriatic arthritis (PsA) is a chronic, immune‐mediated inflammatory musculoskeletal disorder associated with a high prevalence of metabolic syndrome (MetS) (1), a cluster of concurrent risk factors that can lead to higher incidence of cardiovascular (CV) disease and type 2 diabetes (2‐4). According to a 2009 international consensus statement, abnormal findings in at least three of five components (central obesity, elevated triglycerides, reduced high‐density lipoprotein [HDL]‐cholesterol, elevated blood pressure, and elevated fasting glucose) constitute MetS (2). As MetS and its components comprise CV risk factors, these patients should be identified clinically and managed accordingly.MetS is known to be associated with insulin resistance and chronic systemic inflammation (5). Central obesity, the most prevalent manifestation of MetS, may play a role in both, with excess adipose tissue resulting in higher levels of hormones and proinflammatory cytokines such as leptin, interleukin (IL)‐6, and tumor necrosis factor (TNF)‐α (5,6).Elevated levels of leptin, IL‐6, TNF‐α, and other proinflammatory cytokines are also associated with inflammatory diseases, such as PsA (7,8); the prevalence of MetS is significantly higher in patients with PsA than in patients with noninflammatory musculoskeletal disease (9), and the presence of MetS was associated with more severe PsA (1).Of note, patients with both PsA 
TI - Tofacitinib in Patients With Psoriatic Arthritis and Metabolic Syndrome: A Post hoc Analysis of Phase 3 Studies
JO - ACR Open Rheumatology
DO - 10.1002/acr2.11166
DA - 2020-10-01
UR - https://www.deepdyve.com/lp/wiley/tofacitinib-in-patients-with-psoriatic-arthritis-and-metabolic-0C2XLPQDz5
SP - 543
EP - 554
VL - 2
IS - 10
DP - DeepDyve
ER -